KRS Capital Management LLC Decreases Stock Holdings in Danaher Co. (NYSE:DHR)

KRS Capital Management LLC decreased its holdings in shares of Danaher Co. (NYSE:DHR) by 3.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,514 shares of the conglomerate’s stock after selling 50 shares during the quarter. KRS Capital Management LLC’s holdings in Danaher were worth $378,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Cape Investment Advisory Inc. purchased a new stake in shares of Danaher in the fourth quarter valued at $25,000. Tsfg LLC raised its stake in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the period. BKM Wealth Management LLC purchased a new stake in shares of Danaher in the fourth quarter valued at $27,000. Wetzel Investment Advisors Inc. purchased a new position in Danaher in the 4th quarter worth about $29,000. Finally, Rakuten Securities Inc. purchased a new position in Danaher in the 4th quarter worth about $36,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the transaction, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO Matthew Mcgrew sold 46,377 shares of Danaher stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $7,441,441.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the transaction, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The disclosure for this sale can be found here. In the last ninety days, insiders sold 148,783 shares of company stock valued at $37,536,717. 11.10% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts recently commented on DHR shares. Jefferies Financial Group started coverage on shares of Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target on the stock. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and increased their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Robert W. Baird increased their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Finally, Citigroup increased their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

Danaher Stock Performance

DHR stock traded down $1.64 during trading on Friday, reaching $249.85. The company had a trading volume of 4,638,276 shares, compared to its average volume of 3,371,169. The firm has a 50-day simple moving average of $255.96 and a 200-day simple moving average of $246.43. The company has a market cap of $185.06 billion, a price-to-earnings ratio of 42.38, a price-to-earnings-growth ratio of 3.85 and a beta of 0.85. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $269.11.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same period last year, the firm posted $2.36 EPS. Danaher’s revenue for the quarter was down 2.6% compared to the same quarter last year. As a group, sell-side analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.